Which is more profitable, Bristol-Myers Squibb or Novo Nordisk?

Novo Nordisk keeps more of every sale as profit.

Which grows faster, Bristol-Myers Squibb or Novo Nordisk?

Novo Nordisk grew its sales faster in recent years.

Which is cheaper, Bristol-Myers Squibb or Novo Nordisk?

Novo Nordisk costs less for each unit of yearly profit (lower P/E).

Which has less debt, Bristol-Myers Squibb or Novo Nordisk?

Novo Nordisk would need fewer years of earnings to pay off its debt.

Bristol-Myers SquibbBMYvs

Novo NordiskNVO

Bristol-Myers Squibb vs Novo Nordisk stock

Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.

In one sentence

Novo Nordisk is more profitable, grows faster, is cheaper for its profits and has less debt.

Side by side

	Bristol-Myers Squibb	Novo Nordisk
	$130 billion	$184 billion
	14.6%	33.1%
	+2.5%	+20.4%
	18.4×	12.2×
	2.4 years	0.7 years
	13.9%	33.6%
	4.4%	4.2%

Open Bristol-Myers Squibb Open Novo Nordisk

How we compare

Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.

More comparisons: Bristol-Myers Squibb vs Roche · Bristol-Myers Squibb vs Thermo Fisher Scientific · Bristol-Myers Squibb vs UnitedHealth · Bristol-Myers Squibb vs AbbVie · Novo Nordisk vs Johnson & Johnson · Novo Nordisk vs Eli Lilly · Novo Nordisk vs Medtronic · Novo Nordisk vs Roche